25 September 2025

Polypharmacy Impairs Rheumatoid Arthritis Outcomes

A French early rheumatoid arthritis (RA) study has shown that polypharmacy (PP) was associated with significant lower treatment responses and more serious adverse events (SAEs).

Data was drawn from the French ESPOIR study, a prospective study of early RA. Polypharmacy was defined as concurrent use of 2 or more non-RA medications by the patient. The endpoints were the occurrence of SAEs (severe infections, hospitalizations, deaths) throughout a 10-year follow-up period.

OL study of 60 pts w/ new idiopathic retroperitoneal fibrosis (GFR >30) Rx w/ low dose MTX+pred VS Pred only. @ 9 mo

Tweet Author

RheumNow

Tweet Content

OL study of 60 pts w/ new idiopathic retroperitoneal fibrosis (GFR >30) Rx w/ low dose MTX+pred VS Pred only. @ 9 mos remission: 90% MTX+Pred vs 81% Pred (noninferior). Time-to-remission, RPF thickness & relapses were same; but pred use was lower w/ MTX+pred (p < 0.001) https://t.co/13cjnl4Ke4

ILD: Treatment (Part Three) Save

ADD THE FIRST COMMENT

Final session alert! Join us for the closing webinar of our Rheum to Breathe: ILD campaign. ILD experts will share best

Tweet Author

RheumNow

Tweet Content

Final session alert! Join us for the closing webinar of our Rheum to Breathe: ILD campaign. ILD experts will share best practices in diagnosis, screening, and monitoring—from tools & labs to imaging, RA screening & referral strategies. 🗓 Sep 30 | 7PM ET https://t.co/1p5daM1ouh https://t.co/V83McTgHtl

Links

Welcome! You are invited to join a webinar: ILD Diagnosis, Screening and Monito… https://buff.ly/R4OTnGQ

Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition tim

Tweet Author

RheumNow

Tweet Content

Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz

25 September 2025

Malignancies Not Increased with Biologic Therapies

The risk of malignancy in rheumatoid arthritis (RA) patients receiving biologic agents was evaluated by metanalysis of randomized controlled trials (RCTs) and found no significant increased risk of malignancy compared with other disease-modifying antirheumatic drugs (DMARDs) or with placebo.

Canakinumab in VEXAS - 47 males Rx w/ anakinra (44), canakinumab (9), or both(6). Response @1 mos: ANAK 34% vs CANK 100%

Tweet Author

RheumNow

Tweet Content

Canakinumab in VEXAS - 47 males Rx w/ anakinra (44), canakinumab (9), or both(6). Response @1 mos: ANAK 34% vs CANK 100%; 22% vs 78% @ 3 mos. Drug survival was 54 mos CANK 300/m; 7 mo CANK 150/m; 1 mo ANAK. More ISR (47% v 0) & infx w/ ANAK https://t.co/Y3iSfajTal https://t.co/qTNamGDwVI

Links

Comparative efficacy and safety of anakinra and canakinumab in patients with VE… https://buff.ly/fHvXyyQ

Prospective French study of 101 RA-ILD (mean 66yrs) assessed for shorter WBC telomere length (LTL); short LTL seen in 43

Tweet Author

RheumNow

Tweet Content

Prospective French study of 101 RA-ILD (mean 66yrs) assessed for shorter WBC telomere length (LTL); short LTL seen in 43% & assoc w/ lower FVC (82% vs 93%pred) & TLCO (49% vs 63%) & greater FVC/DLCO decline & lung progression after 12 mos (47% vs 22%; p<0.001) https://t.co/ObVeon0riy

Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in

Tweet Author

RheumNow

Tweet Content

Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in ED or hospitalization. But NSIA led to missed work (37%) or RA Rx interruptions (26%) and more fatigue. NSIE may contribute to more disease flares https://t.co/Al5B5oxvFg

24 September 2025

Rheumatoid arthritis begins long before symptoms

Scientists have discovered that rheumatoid arthritis (RA) doesn’t start when the pain begins. It silently starts years earlier.The new research reveals that people at risk for RA experience dramatic immune system changes long before they feel symptoms.  

Topics

Polypharmacy Impairs Rheumatoid Arthritis Outcomes

OL study of 60 pts w/ new idiopathic retroperitoneal fibrosis (GFR >30) Rx w/ low dose MTX+pred VS Pred only. @ 9 mo

ILD: Treatment (Part Three) Save

ADD THE FIRST COMMENT

Final session alert! Join us for the closing webinar of our Rheum to Breathe: ILD campaign. ILD experts will share best

Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition tim

Canakinumab in VEXAS - 47 males Rx w/ anakinra (44), canakinumab (9), or both(6). Response @1 mos: ANAK 34% vs CANK 100%

Prospective French study of 101 RA-ILD (mean 66yrs) assessed for shorter WBC telomere length (LTL); short LTL seen in 43

Monthly survey - 351 ArthritisPower #RA Registry pts reported 523 nonserious infxns (31% ; most URI), few resulted in

Do you get our email newsletter?